These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

966 related articles for article (PubMed ID: 28465485)

  • 1. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
    Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
    Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma.
    Kim KJ; Lee HW; Seong J
    J Gastroenterol Hepatol; 2021 May; 36(5):1357-1365. PubMed ID: 33217056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
    Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
    Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1.
    Park JH; Kim HY; Lee A; Seo YK; Kim IH; Park ET; Kang MS; Park SJ; Park S
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):510-520. PubMed ID: 33383126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.
    Li X; Gao L; Wang B; Hu J; Yu Y; Gu B; Xiang L; Li X; Li H; Zhang T; Wang Y; Ma C; Dong J; Lu J; Lucas A; Chen H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu C; Miao X; Wang Y; Wen L; Cheng X; Kong D; Zhao P; Song D; Wang X; Ding X; Xia H; Wang W; Sun Q; Gong W
    Cancer Sci; 2020 Oct; 111(10):3503-3515. PubMed ID: 32726482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Effects of Anti-PD-L1 and Nanosonodynamic Therapy on HCC Immune Activation in Mice: An Investigation.
    Wei M; Wang X; Mo Y; Kong C; Zhang M; Qiu G; Tang Z; Chen J; Wu F
    Int J Nanomedicine; 2024; 19():7215-7236. PubMed ID: 39050875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
    Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
    Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
    Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
    Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.